Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies

Lung cancer resistance is commonly attributed to acquired genetic alterations, including on-target mutations, activation of bypass pathways, tumor-suppressor loss, and histologic or lineage transformation. However, genetic evolution alone cannot fully account for the rapid, reversible, and heterogeneous adaptations that emerge during treatment. Epigenetic plasticity, mediated through DNA methylation, histone modifications, chromatin-remodeling complexes, and transcriptional state transitions, enables tumor cells to enter drug-tolerant states, alter lineage identity, evade immune surveillance, and persist under therapeutic pressure, creating conditions in which more stable forms of resistance can develop. This review examines how epigenetic programs interact with oncogenic drivers and tumor-suppressor loss to shape therapy resistance across lung cancer. We discuss chromatin-mediated resistance to targeted therapies, cytotoxic chemotherapy, and immune checkpoint blockade, with particular attention to drug-tolerant persister states, epithelial–mesenchymal and neuroendocrine transitions, impaired antigen presentation, and remodeling of the tumor microenvironment. We critically assess the evidence for DNA methyltransferase and histone deacetylase inhibitors, together with emerging strategies targeting EZH2/EZH1, LSD1, BET proteins, PRMT5/MAT2A, and vulnerabilities associated with SWI/SNF dysfunction. Clinical translation has been limited by modest single-agent activity, treatment-related toxicity, incomplete pharmacodynamic assessment, and inadequate biomarker-based patient selection. Future progress will depend on matching epigenetic interventions to defined biological states, confirming intratumoral target engagement, and integrating longitudinal multiomic profiling to guide patient selection, treatment sequencing, and early interception of emerging resistance.

Authors

Institutions

Publication Details

Journal
Genes
Published
2026-11-16
DOI
https://doi.org/10.3390/genes17111442
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies

Haiying Cheng, Meng Wang, Jihua Yang, Buse Eglenen Polat et al.
3 links
Genes
Epigenetics and DNA Methylation
article

Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies

Haiying Cheng, Meng Wang, Jihua Yang, Buse Eglenen Polat, Renuka Meenu Ramchandran
article en

Abstract

Lung cancer resistance is commonly attributed to acquired genetic alterations, including on-target mutations, activation of bypass pathways, tumor-suppressor loss, and histologic or lineage transformation. However, genetic evolution alone cannot fully account for the rapid, reversible, and heterogeneous adaptations that emerge during treatment. Epigenetic plasticity, mediated through DNA methylation, histone modifications, chromatin-remodeling complexes, and transcriptional state transitions, enables tumor cells to enter drug-tolerant states, alter lineage identity, evade immune surveillance, and persist under therapeutic pressure, creating conditions in which more stable forms of resistance can develop. This review examines how epigenetic programs interact with oncogenic drivers and tumor-suppressor loss to shape therapy resistance across lung cancer. We discuss chromatin-mediated resistance to targeted therapies, cytotoxic chemotherapy, and immune checkpoint blockade, with particular attention to drug-tolerant persister states, epithelial–mesenchymal and neuroendocrine transitions, impaired antigen presentation, and remodeling of the tumor microenvironment. We critically assess the evidence for DNA methyltransferase and histone deacetylase inhibitors, together with emerging strategies targeting EZH2/EZH1, LSD1, BET proteins, PRMT5/MAT2A, and vulnerabilities associated with SWI/SNF dysfunction. Clinical translation has been limited by modest single-agent activity, treatment-related toxicity, incomplete pharmacodynamic assessment, and inadequate biomarker-based patient selection. Future progress will depend on matching epigenetic interventions to defined biological states, confirming intratumoral target engagement, and integrating longitudinal multiomic profiling to guide patient selection, treatment sequencing, and early interception of emerging resistance.

GenesVol. 17(11)
Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Montefiore Einstein Comprehensive Cancer Center (US)
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon